Synthesis and Anti-HIV-1 Activity Evaluation for Novel 3a,6a-Dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione Derivatives
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synthesis and Anti-HIV-1 Activity Evaluation for Novel 3a,6a-Dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione Derivatives
Authors
Keywords
-
Journal
MOLECULES
Volume 21, Issue 9, Pages 1198
Publisher
MDPI AG
Online
2016-09-08
DOI
10.3390/molecules21091198
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends
- (2015) Peng Zhan et al. JOURNAL OF MEDICINAL CHEMISTRY
- 4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1
- (2014) Xue Zhi Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency against Cells Harboring Raltegravir-Resistant Integrase Mutants
- (2014) Xue Zhi Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Azvudine, A Novel Nucleoside Reverse Transcriptase Inhibitor Showed Good Drug Combination Features and Better Inhibition on Drug-Resistant Strains than Lamivudine In Vitro
- (2014) Rui-Rui Wang et al. PLoS One
- Dolutegravir: First Global Approval
- (2013) Anita D. Ballantyne et al. DRUGS
- Next-Generation Integrase Inhibitors
- (2013) Sharon L. Karmon et al. DRUGS
- Inhibiting the HIV Integration Process: Past, Present, and the Future
- (2013) Roberto Di Santo JOURNAL OF MEDICINAL CHEMISTRY
- DB-02, a C-6-Cyclohexylmethyl Substituted Pyrimidinone HIV-1 Reverse Transcriptase Inhibitor with Nanomolar Activity, Displays an Improved Sensitivity against K103N or Y181C Than S-DABOs
- (2013) Xing-Jie Zhang et al. PLoS One
- Naphthyridinone (NTD) integrase inhibitors: N1 Protio and methyl combination substituent effects with C3 amide groups
- (2012) Brian A. Johns et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Emerging patterns and implications of HIV-1 integrase inhibitor resistance
- (2012) Anna Maria Geretti et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Dolutegravir for the treatment of HIV
- (2012) Christine Katlama et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
- (2011) Kendra E. Hightower et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structural insights into the retroviral DNA integration apparatus
- (2011) Peter Cherepanov et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Resistance to Integrase Inhibitors
- (2010) Mathieu Métifiot et al. Viruses-Basel
- Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo
- (2009) O. Delelis et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-ones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones
- (2009) Xue Zhi Zhao et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Synthesis and in Vitro Evaluation of N-Substituted Maleimide Derivatives as Selective Monoglyceride Lipase Inhibitors
- (2009) Nicolas Matuszak et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection
- (2008) Vincenzo Summa et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started